Azitra, Inc. (AZTR)Healthcare | Biotechnology | Branford, United States | NYSE American
0.07 USD
|
Hot Take ↕ | Oct. 10, 2026, 6:53 a.m. EDT
The immediate outlook is severely clouded by a catastrophic multi-year price collapse, which serves as the market's definitive verdict on the company's deteriorating prospects. Despite a recent spike driven by a CEO-backed private placement and insider buying, the stock has lost nearly 99.7% of its value over the last two years, with the most recent annual period seeing another massive drop of roughly 79%. This relentless downward trajectory, compounded by negative earnings, negative free cash flow, and a forward P/E that indicates no expected profitability, suggests the business fundamentals are failing rather than merely undervalued. The recent price jump appears to be a liquidity event or a desperate attempt to raise capital rather than a sign of operational recovery, especially given the heavy discount to the analyst mean target which implies significant future growth that the current financials do not support. With no dividend history to speak of and a balance sheet showing significant cash burn relative to its tiny market cap, there is no margin of safety here; the price action confirms that investors are fleeing the asset. The statistical forecast model offers no help, citing very low confidence due to the extreme volatility and noise inherent in such a distressed trading environment. Consequently, the short-term view remains bearish as the stock struggles to find a floor, and the long-term view is even more dire, as the structural damage to the equity value is profound. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.175742 |
| MSTL | 0.183230 |
| AutoARIMA | 0.446793 |
| AutoTheta | 0.461442 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 19.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | -1.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.591 |
| Market Cap | 4,333,168 |
| Forward P/E | -0.14 |
| Beta | -1.04 |
| Previous Name | Azitra Inc |
| Website | https://azitrainc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.898017 |
| Address1 | 21 Business Park Drive |
| All Time High | 1,036.0 |
| All Time Low | 0.052 |
| Ask | 0.0739 |
| Ask Size | 500 |
| Average Daily Volume10 Day | 794,140 |
| Average Daily Volume3 Month | 1,676,423 |
| Average Volume | 1,676,423 |
| Average Volume10Days | 794,140 |
| Beta | -1.04 |
| Bid | 0.07 |
| Bid Size | 200 |
| Book Value | 0.121 |
| City | Branford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0715 |
| Current Ratio | 4.863 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.1213 |
| Day Low | 0.0518 |
| Debt To Equity | 5.591 |
| Display Name | Azitra |
| Dividend Yield | 0.0 |
| Ebitda | -12,201,906 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.163 |
| Enterprise Value | -1,984,589 |
| Eps Forward | -0.52 |
| Eps Trailing Twelve Months | -0.28 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.15178 |
| Fifty Day Average Change | -0.08027999 |
| Fifty Day Average Change Percent | -0.5289234 |
| Fifty Two Week Change Percent | -89.8017 |
| Fifty Two Week High | 1.09 |
| Fifty Two Week High Change | -1.0185001 |
| Fifty Two Week High Change Percent | -0.9344037 |
| Fifty Two Week Low | 0.0518 |
| Fifty Two Week Low Change | 0.019700002 |
| Fifty Two Week Low Change Percent | 0.3803089 |
| Fifty Two Week Range | 0.0518 - 1.09 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,686,922,200,000 |
| Float Shares | 51,252,585 |
| Forward Eps | -0.52 |
| Forward P E | -0.13750002 |
| Free Cashflow | -7,242,045 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 13 |
| Fullday Change | -0.046099998 |
| Fullday Change Percent | -39.200676 |
| Fullday Price | 0.0715 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07593 |
| Held Percent Institutions | 0.32041 |
| Implied Shares Outstanding | 60,603,742 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,755,734,400 |
| Last Split Factor | 15:100 |
| Long Business Summary | Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut. |
| Long Name | Azitra, Inc. |
| Market | us_market |
| Market Cap | 4,333,168 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_404021170 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -12,272,932 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,029,919 |
| Number Of Analyst Opinions | 2 |
| Open | 0.1207 |
| Operating Cashflow | -11,105,767 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 203 646 6446 |
| Prev Name | Azitra Inc |
| Previous Close | 0.0715 |
| Price Hint | 4 |
| Price To Book | 0.5909091 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.49 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.1213 |
| Regular Market Day Low | 0.0518 |
| Regular Market Day Range | 0.0518 - 0.1213 |
| Regular Market Open | 0.1207 |
| Regular Market Previous Close | 0.0715 |
| Regular Market Price | 0.0715 |
| Regular Market Time | 1,791,985,562 |
| Regular Market Volume | 2,670,553 |
| Return On Assets | -1.19912 |
| Return On Equity | -2.56667 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 60,603,742 |
| Shares Percent Shares Out | 0.004 |
| Shares Short | 240,809 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,368,917 |
| Short Name | Azitra Inc |
| Short Percent Of Float | 0.0044 |
| Short Ratio | 0.34 |
| Source Interval | 15 |
| State | CT |
| Symbol | AZTR |
| Target High Price | 1.0 |
| Target Low Price | 0.34 |
| Target Mean Price | 0.67 |
| Target Median Price | 0.67 |
| Total Cash | 6,727,810 |
| Total Cash Per Share | 0.111 |
| Total Debt | 410,053 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.19632 |
| Two Hundred Day Average Change | -0.124819994 |
| Two Hundred Day Average Change Percent | -0.6357987 |
| Type Disp | Equity |
| Volume | 2,670,553 |
| Website | https://azitrainc.com |
| Zip | 6,405 |